How to Value an Oncology Practice in 2026

Oncology is the single highest-value physician specialty in M&A, and it's not particularly close. Where a primary care practice might trade at 4-6x EBITDA and a cardiology group at 7-10x, oncology practices with established infusion centers routinely command 8-15x EBITDA — and platform acquisitions by well-capitalized PE firms have pushed above that range. The reason is simple: oncology practices generate revenue density that no other specialty can match, primarily through chemotherapy drug administration.

I've advised on oncology transactions ranging from solo medical oncologists to multi-site groups with 20+ providers, and the valuation dynamics are unlike anything else in healthcare M&A. If you own an oncology practice, this is what you need to understand about how buyers will value it.

The Buy-and-Bill Model: Why Oncology Prints Money

The core economic engine of an oncology practice is the buy-and-bill model for chemotherapy drugs. Your practice purchases oncology drugs at wholesale (typically at ASP or below), administers them to patients in your infusion center, and bills Medicare and commercial payers at ASP + 6% (for Medicare Part B) or negotiated commercial rates that are often significantly higher. The spread between acquisition cost and reimbursement is the profit margin, and for high-cost drugs like pembrolizumab, bevacizumab, or trastuzumab, that spread can be enormous.

A single infusion chair generating $800K-$1.2M in annual drug revenue is not unusual for a busy community oncology practice. A 15-chair infusion center can produce $10-18M in drug revenue alone, before you count evaluation and management visits, radiation therapy, imaging, or lab work. Buyers understand this math intimately, and it's why oncology practices are valued on a fundamentally different plane than other medical practices.

The critical nuance is drug margin exposure. Medicare's ASP+6% formula is well-established but periodically targeted for reform. Commercial payer contracts vary wildly — some pay a percentage of AWP, some pay ASP plus a fixed dollar amount, some have carved out oncology drugs entirely. Buyers will dissect your payer contract details more carefully than in any other specialty. Your commercial payer mix and the specific drug reimbursement terms in each contract can swing your valuation by 2-3x multiples.

Radiation Therapy: The Equipment Question

Oncology practices with radiation therapy capabilities — linear accelerators, CyberKnife, proton therapy — present a unique valuation challenge because the equipment represents both enormous value and enormous capital risk. A single modern linear accelerator costs $3-5M installed. A CyberKnife system runs $5-7M. Proton therapy installations can exceed $100M, though those are exclusively hospital-based.

Buyers evaluate radiation equipment on three axes: age, utilization, and technology generation. A five-year-old Varian TrueBeam running at 80% capacity is a cash flow machine. A twelve-year-old linear accelerator approaching end-of-life is a $4M replacement liability that buyers will deduct from their offer. I've seen equipment age swing oncology valuations by $3-10M depending on what needs replacing in the next three to five years.

The strategic question for sellers is whether to invest in new equipment before selling. My advice: if your linear accelerator has 3+ years of useful life remaining, don't replace it — let the buyer make that decision with their own capital plan. But if you're running equipment that's approaching obsolescence, the valuation haircut you'll take without upgrading usually exceeds the cost of the upgrade. Run the numbers both ways.

Clinical Trial Revenue: The Valuation Accelerator

Clinical trial participation is the factor that separates a good oncology practice from a great one in the eyes of buyers. Pharma companies pay $25,000-$75,000 per patient enrolled in an oncology clinical trial, and active trial sites with robust research infrastructure generate $1-5M+ in annual clinical trial revenue with margins north of 40%.

But the value goes beyond direct revenue. Clinical trial capability signals three things to buyers: your physicians are at the cutting edge of treatment protocols, your practice has the infrastructure (research coordinators, IRB relationships, data management systems) to handle complexity, and you attract patients who specifically seek out trial access — often the most engaged and treatment-adherent patients in the population.

Practices with active clinical trial programs consistently trade at the top of the multiple range. I've seen trial revenue valued at 1.5-2x the multiple applied to the rest of the practice's EBITDA, because buyers view it as a growth engine they can scale post-acquisition. If you have trial capability but aren't maximizing it, ramping up trial enrollment 12-18 months before a sale is one of the highest-ROI moves you can make.

Provider Depth and Succession Risk

Oncology has a provider shortage problem that directly impacts valuations. Medical oncologists require 5-6 years of training after medical school, and the pipeline doesn't produce enough to meet demand — particularly in community settings outside academic medical centers. This scarcity creates both risk and opportunity for sellers.

A solo medical oncologist practice, no matter how profitable, will face a discount for owner dependency. If you are the only oncologist and you leave, patients will migrate to the nearest alternative within weeks — cancer treatment can't wait for a recruitment cycle. Buyers know this and will either demand an extended employment agreement (3-5 years is standard in oncology) or discount the multiple by 2-3x.

Practices with three or more medical oncologists, plus advanced practice providers handling surveillance visits and supportive care, are far more resilient. The loss of any single provider doesn't threaten the patient base. This provider depth is one of the primary reasons multi-physician oncology groups command platform-level multiples (12-15x EBITDA) while solo oncologists trade at 6-8x.

Radiation oncologists add another layer. If your group includes both medical and radiation oncology, you're offering buyers a complete cancer care platform — diagnosis through treatment — which eliminates the leakage that occurs when medical oncology has to refer out for radiation. Integrated groups trade at a meaningful premium.

The Buyer Landscape in Oncology M&A

Oncology attracts the most sophisticated buyers in healthcare M&A. OneOncology (backed by TPG), American Oncology Network, US Oncology (McKesson), and Flatiron Health (Roche) are all actively acquiring community oncology practices. These aren't generalist physician management companies — they understand the economics of buy-and-bill, drug sourcing, and payer contracting at a level that makes negotiations genuinely technical.

What these platforms are buying is scale. Scale in drug purchasing (GPO leverage drives down acquisition cost), scale in payer negotiation (larger networks get better commercial rates), and scale in clinical trials (pharma sponsors prefer large multi-site research networks). Your practice's strategic value to a platform is partially about your current cash flow and partially about how much incremental value they can extract by plugging you into their infrastructure.

Hospital systems are the other major buyer category. Academic medical centers and large health systems have been acquiring community oncology practices to protect referral patterns and capture the drug margin for their own pharmacy benefit. Hospital-employed oncologists often see their drug reimbursement shift to hospital outpatient rates, which are significantly higher than physician office rates — a margin arbitrage that funds the acquisition.

Preparing an Oncology Practice for Sale

If you're 18-24 months from a transaction, here are the highest-impact moves for oncology specifically.

Audit your drug margin by payer. Pull every infusion claim for the last 12 months and calculate the actual spread between drug acquisition cost and reimbursement by payer. Buyers will do this in diligence anyway — having it prepared and clean shows sophistication and accelerates the process.

Document your equipment lifecycle.Create a capital expenditure forecast showing the age, utilization, and expected replacement timeline for every piece of major equipment. Buyers want to see that you've planned for replacement, not that you've been deferring it.

Lock in your providers.Ensure your oncologists have employment agreements with reasonable non-competes and retention incentives. The single biggest deal-killer in oncology M&A is a physician who threatens to leave during the process.

Ramp clinical trials.If you have a research department, maximize enrollment. If you don't, consider whether standing up a small trial program (even 5-10 active protocols) could meaningfully increase your attractiveness to platform buyers.

Understand your ancillary revenue.Many oncology practices generate significant revenue from PET/CT imaging, laboratory services, genetic testing, and supportive care infusions (hydration, blood transfusions). Make sure these revenue streams are clearly broken out in your financials — they're often undervalued when lumped into general practice revenue.

The Bottom Line

Oncology practices sit at the top of the healthcare M&A value chain because they combine high revenue density, defensible market positions (cancer patients need treatment regardless of the economy), and multiple revenue streams that sophisticated buyers know how to optimize. The 8-15x EBITDA range is real, but where you fall within it depends on your drug margins, provider depth, equipment condition, clinical trial activity, and payer mix. Getting these elements right before going to market is the difference between a good exit and an exceptional one.